150.97
price down icon0.81%   -1.24
after-market Dopo l'orario di chiusura: 152.00 1.03 +0.68%
loading
Precedente Chiudi:
$152.21
Aprire:
$152.36
Volume 24 ore:
1.33M
Relative Volume:
0.85
Capitalizzazione di mercato:
$22.13B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
14.44
EPS:
10.453
Flusso di cassa netto:
$1.85B
1 W Prestazione:
-2.11%
1M Prestazione:
+6.81%
6M Prestazione:
+32.37%
1 anno Prestazione:
-17.19%
Intervallo 1D:
Value
$149.64
$152.36
Intervallo di 1 settimana:
Value
$149.64
$160.20
Portata 52W:
Value
$110.03
$194.13

Biogen Inc Stock (BIIB) Company Profile

Name
Nome
Biogen Inc
Name
Telefono
(781) 464-2000
Name
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Name
Dipendente
7,605
Name
Cinguettio
@biogen
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
BIIB's Discussions on Twitter

Confronta BIIB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
150.97 22.32B 9.61B 1.53B 1.85B 10.45
Drug Manufacturers - General icon
LLY
Lilly Eli Co
845.72 756.28B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
189.69 454.91B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
231.24 411.31B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.31 254.66B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.40 218.83B 63.43B 16.42B 14.72B 6.4861

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-25 Iniziato Jefferies Buy
2025-07-21 Ripresa Truist Hold
2025-04-28 Downgrade HSBC Securities Buy → Hold
2025-04-04 Downgrade Argus Buy → Hold
2025-02-11 Iniziato Bernstein Mkt Perform
2025-01-02 Downgrade Piper Sandler Overweight → Neutral
2024-12-20 Downgrade BMO Capital Markets Outperform → Market Perform
2024-12-16 Downgrade Stifel Buy → Hold
2024-12-10 Ripresa BofA Securities Neutral
2024-12-09 Downgrade Jefferies Buy → Hold
2024-11-18 Downgrade Needham Buy → Hold
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-14 Iniziato Citigroup Neutral
2024-10-31 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-10-10 Ripresa Raymond James Mkt Perform
2024-02-14 Reiterato Needham Buy
2024-02-14 Downgrade Wells Fargo Overweight → Equal Weight
2024-01-24 Downgrade UBS Buy → Neutral
2023-12-20 Ripresa Cantor Fitzgerald Overweight
2023-12-07 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-06 Iniziato HSBC Securities Buy
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-07-24 Reiterato UBS Buy
2023-05-01 Aggiornamento Guggenheim Neutral → Buy
2023-04-17 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-26 Aggiornamento Goldman Neutral → Buy
2022-10-13 Aggiornamento Stifel Hold → Buy
2022-10-07 Aggiornamento Argus Hold → Buy
2022-09-28 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-09-28 Aggiornamento Mizuho Neutral → Buy
2022-09-28 Aggiornamento Robert W. Baird Neutral → Outperform
2022-04-18 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-03-08 Downgrade Stifel Buy → Hold
2022-03-03 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-04 Reiterato Barclays Equal Weight
2022-02-04 Reiterato BofA Securities Neutral
2022-02-04 Reiterato Cowen Outperform
2022-02-04 Reiterato Morgan Stanley Overweight
2022-02-04 Reiterato Needham Buy
2022-02-04 Reiterato Oppenheimer Outperform
2022-02-04 Reiterato RBC Capital Mkts Sector Perform
2022-02-04 Reiterato Robert W. Baird Neutral
2022-02-04 Reiterato Wedbush Neutral
2022-02-04 Reiterato Wells Fargo Equal Weight
2022-02-04 Reiterato Wolfe Research Peer Perform
2022-01-13 Downgrade Guggenheim Buy → Neutral
2022-01-12 Downgrade Piper Sandler Overweight → Neutral
2021-12-10 Ripresa Raymond James Mkt Perform
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-09-23 Iniziato Needham Buy
2021-06-18 Aggiornamento Piper Sandler Neutral → Overweight
2021-06-14 Reiterato Truist Buy
2021-06-11 Aggiornamento Bernstein Mkt Perform → Outperform
2021-06-10 Aggiornamento UBS Neutral → Buy
2021-06-08 Aggiornamento Atlantic Equities Underweight → Neutral
2021-06-08 Reiterato Barclays Equal Weight
2021-06-08 Aggiornamento Citigroup Sell → Neutral
2021-06-08 Reiterato H.C. Wainwright Buy
2021-06-08 Reiterato Jefferies Buy
2021-06-08 Reiterato Morgan Stanley Overweight
2021-06-08 Reiterato RBC Capital Mkts Sector Perform
2021-06-08 Aggiornamento Robert W. Baird Underperform → Neutral
2021-06-08 Reiterato Stifel Buy
2021-06-08 Aggiornamento William Blair Mkt Perform → Outperform
2021-06-07 Aggiornamento BofA Securities Underperform → Neutral
2021-06-07 Aggiornamento Cowen Market Perform → Outperform
2021-06-07 Aggiornamento Raymond James Underperform → Mkt Perform
2021-02-05 Downgrade DZ Bank Buy → Hold
2021-01-29 Aggiornamento Stifel Hold → Buy
2020-11-10 Aggiornamento DZ Bank Hold → Buy
2020-11-09 Downgrade Atlantic Equities Neutral → Underweight
2020-11-09 Downgrade BofA Securities Neutral → Underperform
2020-11-09 Downgrade Cowen Outperform → Market Perform
2020-11-09 Reiterato H.C. Wainwright Buy
2020-11-04 Aggiornamento BofA Securities Underperform → Neutral
2020-11-04 Aggiornamento Jefferies Hold → Buy
2020-11-04 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-10-28 Iniziato UBS Neutral
2020-07-27 Aggiornamento Morgan Stanley Underweight → Overweight
2020-06-22 Downgrade Barclays Overweight → Equal Weight
2020-06-22 Reiterato RBC Capital Mkts Sector Perform
2020-06-09 Downgrade Bernstein Outperform → Mkt Perform
2020-04-23 Downgrade Citigroup Neutral → Sell
2020-04-23 Downgrade Raymond James Mkt Perform → Underperform
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-27 Aggiornamento Canaccord Genuity Hold → Buy
2019-12-13 Aggiornamento Credit Suisse Underperform → Neutral
2019-12-02 Downgrade Robert W. Baird Neutral → Underperform
Mostra tutto

Biogen Inc Borsa (BIIB) Ultime notizie

pulisher
05:20 AM

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com

05:20 AM
pulisher
12:12 PM

Can BMYs Neuroscience Portfolio Help to Diversify Its Business? - The Globe and Mail

12:12 PM
pulisher
10:16 AM

Biogen stock price target lowered to $217 from $219 at RBC Capital - Investing.com UK

10:16 AM
pulisher
09:33 AM

Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $217.00 - MarketBeat

09:33 AM
pulisher
08:08 AM

Central Nervous System Biomarkers Market Growth & Industry - openPR.com

08:08 AM
pulisher
07:51 AM

Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat

07:51 AM
pulisher
04:48 AM

Biogen Inc. $BIIB Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat

04:48 AM
pulisher
03:57 AM

Ascent Group LLC Takes $341,000 Position in Biogen Inc. $BIIB - MarketBeat

03:57 AM
pulisher
Oct 07, 2025

Biogen Says Investors Can't Expand Alzheimer's Drug Suit - Law360

Oct 07, 2025
pulisher
Oct 07, 2025

Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syn - PharmiWeb.com

Oct 07, 2025
pulisher
Oct 07, 2025

Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus

Oct 07, 2025
pulisher
Oct 07, 2025

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - Yahoo Finance

Oct 07, 2025
pulisher
Oct 07, 2025

Bioarctic's Leqembi Maintenance Therapy Launched in the United States - MarketScreener

Oct 07, 2025
pulisher
Oct 06, 2025

Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Leqembi Iqlik subcutaneous injection now available in US By Investing.com - Investing.com Australia

Oct 06, 2025
pulisher
Oct 06, 2025

Biogen Inc. stock underperforms Monday when compared to competitors - MSN

Oct 06, 2025
pulisher
Oct 06, 2025

Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S. - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Leqembi Iqlik subcutaneous injection now available in US - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Eisai and Biogen Launch LEQEMBI Companion™ Program to Enhance Resources for Alzheimer's Disease Treatment - Quiver Quantitative

Oct 06, 2025
pulisher
Oct 06, 2025

Biogen told to pay $124M in patent dispute with Genentech - Fierce Pharma

Oct 06, 2025
pulisher
Oct 06, 2025

Rothschild & Co Redburn Increases Biogen (NASDAQ:BIIB) Price Target to $150.00 - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Rothschild & Co Redburn Adjusts Price Target on Biogen to $150 From $149, Maintains Neutral Rating - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

In Vitro Monoclonal Antibodies Market to hit US$ 8.4 Billion - openPR.com

Oct 06, 2025
pulisher
Oct 06, 2025

Acetylcholinesterase Inhibitors Market to hit US$ 9.03 Billion - openPR.com

Oct 06, 2025
pulisher
Oct 06, 2025

Can Biogen Inc. stock double in next 5 yearsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Grimes & Company Inc. Sells 18,310 Shares of Biogen Inc. $BIIB - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

J. Safra Sarasin Holding AG Sells 7,635 Shares of Biogen Inc. $BIIB - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Mirae Asset Global Investments Co. Ltd. Raises Holdings in Biogen Inc. $BIIB - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Is Biogen Inc. stock a defensive play in 2025Oil Prices & Verified Swing Trading Watchlist - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

A Look at Biogen (BIIB) Valuation Following Australian LEQEMBI Approval and Fresh Analyst Optimism - simplywall.st

Oct 05, 2025
pulisher
Oct 04, 2025

Biogen Idec : Biogen Idec Named Top Employer by Science Magazine - MarketScreener

Oct 04, 2025
pulisher
Oct 04, 2025

Day 6 of Gains Streak for Biogen Stock with 18% Return (vs. 4.6% YTD) [10/3/2025] - Trefis

Oct 04, 2025
pulisher
Oct 03, 2025

Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Oct 03, 2025
pulisher
Oct 03, 2025

Biogen (BIIB) Gains as LEQEMBI Wins Australian Approval for Early Alzheimer’s Treatment - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

[Updated 2026] Biotechnology Market Size & Sector Scope 2032 - openPR.com

Oct 03, 2025
pulisher
Oct 03, 2025

Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT - MSN

Oct 03, 2025
pulisher
Oct 03, 2025

Biogen must pay $88 million more for use of infamous Cabilly patent - IAM Patent

Oct 03, 2025
pulisher
Oct 03, 2025

Could Eisai Partnership and New LEQEMBI Approval Reshape Biogen's (BIIB) Alzheimer's Strategy? - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

United States SMN1 Gene Replacement Market is expected to reach - openPR.com

Oct 03, 2025
pulisher
Oct 03, 2025

Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength? - Yahoo Finance

Oct 03, 2025
pulisher
Oct 03, 2025

Biogen Inc. $BIIB Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Greenleaf Trust Raises Holdings in Biogen Inc. $BIIB - MarketBeat

Oct 03, 2025
pulisher
Oct 02, 2025

6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com

Oct 02, 2025
pulisher
Oct 02, 2025

Biogen’s Global Expansion and Promising Data Fuel Alzheimer’s Treatment Optimism - AD HOC NEWS

Oct 02, 2025
pulisher
Oct 01, 2025

Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns - FinancialContent

Oct 01, 2025
pulisher
Oct 01, 2025

Biogen owes Genentech $88 million in MS drug dispute, US judge says - Reuters

Oct 01, 2025
pulisher
Oct 01, 2025

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 01, 2025
pulisher
Oct 01, 2025

Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years - Benzinga

Oct 01, 2025
pulisher
Oct 01, 2025

Biogen’s Bold Moves: Navigating the Market Waves - StocksToTrade

Oct 01, 2025
pulisher
Oct 01, 2025

Biogen (NASDAQ:BIIB) Trading 8.1% HigherStill a Buy? - MarketBeat

Oct 01, 2025

Biogen Inc Azioni (BIIB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$48.80
price down icon 0.80%
drug_manufacturers_general PFE
$25.68
price down icon 2.25%
$118.25
price up icon 1.26%
$294.62
price down icon 0.31%
drug_manufacturers_general NVO
$59.61
price up icon 1.00%
drug_manufacturers_general MRK
$86.40
price down icon 1.38%
Capitalizzazione:     |  Volume (24 ore):